PIONeeR aims to overcome the resistance to anti-PD-1 therapies in advanced Non-Small Cell Lung Cancer (NSCLC) through a global strategy based on:
- a comprehensive biomarkers assessment on tumor biopsies;
- an early-phase randomized clinical trial comparing several a new Immune Checkpoint Inhibitors (ICI) combination and a control arm (docetaxel) for patients with tumors progressing within 12 weeks of anti-PD-1 treatment initiation;
- the development and validation of new ICI candidates.
PIONeeR brings together cutting-edge projects from MI-FHU leaders in academic (E. Vivier, B. Malissen, D. Olive), translational (F. Romagné) and clinical (F. Barlesi) immuno-oncology, with important contributions from industrial and academic partners (AstraZeneca, Innate-Pharma, HalioDX, Imcheck Therapeutics, Novadiscovery and Centre Leon Berard).